The effect of TNFa-blockers on B-cells in patients with granulomatous diseases.

The effect of TNFa-blockers on B-cells in patients with granulomatous diseases. - TNFa-blockers and B-cells in granulomatous diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41509

Enrollment

Registered

2014-03-13

Start date

2014-04-03

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory systemic diseases

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age > 18 years Biopsy proven sytemic granulomatous disease as Crohn's Disease/Sarcoidosis Intention to start treatment with TNFa-blockers; infliximab

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Primary

Measure	Time frame
To assess the B-cell maturation in patients with granulomatous diseases.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results